Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacek Gronwald

Showing results (181-190 of 307) with videos related to

Pageof 31
Sort By:
Journal of the National Cancer Institute|December 17, 2025
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2Joanne Kotsopoulos, Marta Seca, Jacek Gronwald, et al.
Cancers|November 13, 2021
Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?Klaudia Stempa, Dominika Wokołorczyk, Wojciech Kluźniak, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>Joanne Kotsopoulos, Adriana I Apostol, Kelly Metcalfe, et al.
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|December 20, 2007
BRCA1 mutations and prostate cancer in PolandCezary Cybulski, Bohdan Górski, Jacek Gronwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>Adriana I Apostol, Jacek Gronwald, Cezary Cybulski, et al.
Antioxidants (Basel, Switzerland)|July 27, 2024
Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation CarriersMilena Matuszczak, Adam Kiljańczyk, Wojciech Marciniak, et al.
Nutrients|June 19, 2024
Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 CarriersAdam Kiljańczyk, Milena Matuszczak, Wojciech Marciniak, et al.
Familial Cancer|September 4, 2014
Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern EuropeNatalia Bogdanova, Alexandr V Togo, Magdalena Ratajska, et al.
Antioxidants (Basel, Switzerland)|May 25, 2024
Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation CarriersMilena Matuszczak, Adam Kiljańczyk, Wojciech Marciniak, et al.
Pageof 31

Showing results (181-190 of 307) with videos related to

Sort By:
Pageof 31
Journal of the National Cancer Institute|December 17, 2025
Menopausal hormone therapy and the risk of breast cancer in women with a pathogenic variant in BRCA1 or BRCA2Joanne Kotsopoulos, Marta Seca, Jacek Gronwald, et al.
Cancers|November 13, 2021
Do BARD1 Mutations Confer an Elevated Risk of Prostate Cancer?Klaudia Stempa, Dominika Wokołorczyk, Wojciech Kluźniak, et al.
Current Oncology (Toronto, Ont.)|December 24, 2025
The Risk of Breast Cancer According to Mutation Type and Position in Carriers of a Pathogenic Variant in <i>BRCA1</i>Joanne Kotsopoulos, Adriana I Apostol, Kelly Metcalfe, et al.
JAMA Oncology|February 29, 2024
Bilateral Oophorectomy and All-Cause Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJoanne Kotsopoulos, Jacek Gronwald, Tomasz Huzarski, et al.
European Journal of Cancer Prevention : the Official Journal of the European Cancer Prevention Organisation (ECP)|December 20, 2007
BRCA1 mutations and prostate cancer in PolandCezary Cybulski, Bohdan Górski, Jacek Gronwald, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 28, 2026
Risk of Breast Cancer After Ovarian Cancer in Women With a Pathogenic/Likely Pathogenic Variant in <i>BRCA1</i> or <i>BRCA2</i>Adriana I Apostol, Jacek Gronwald, Cezary Cybulski, et al.
Antioxidants (Basel, Switzerland)|July 27, 2024
Antioxidant Properties of Zinc and Copper-Blood Zinc-to Copper-Ratio as a Marker of Cancer Risk BRCA1 Mutation CarriersMilena Matuszczak, Adam Kiljańczyk, Wojciech Marciniak, et al.
Nutrients|June 19, 2024
Blood Iodine as a Potential Marker of the Risk of Cancer in BRCA1 CarriersAdam Kiljańczyk, Milena Matuszczak, Wojciech Marciniak, et al.
Familial Cancer|September 4, 2014
Prevalence of the BLM nonsense mutation, p.Q548X, in ovarian cancer patients from Central and Eastern EuropeNatalia Bogdanova, Alexandr V Togo, Magdalena Ratajska, et al.
Antioxidants (Basel, Switzerland)|May 25, 2024
Zinc and Its Antioxidant Properties: The Potential Use of Blood Zinc Levels as a Marker of Cancer Risk in BRCA1 Mutation CarriersMilena Matuszczak, Adam Kiljańczyk, Wojciech Marciniak, et al.
Pageof 31